:format(webp)/cdn.mskdoctors.com/storage/2026/7/QrfuPSrluQSuTfY26E2s7bPfm9fOFncs.jpg)
ChondroFiller injection safety: what the evidence showsOver 19,000 ChondroFiller injections have been administered globally with no serious adverse effects reported; reoperation rates of 3–8% fall well below surgical alternatives such as microfracture (up to 41%) and ACI/MACI (up to 37%).Over 19,000 ChondroFiller injections have been administered globally with no serious adverse effects reported; reoperation rates of 3–8% fall well below surgical alternatives such as microfracture (up to 41%) and ACI/MACI (up to 37%).
:format(webp)/cdn.mskdoctors.com/storage/2026/7/UY0InSBaoOinSJHR9T3qmZrV7DMIQOXA.jpg)
ChondroFiller vs PRP for focal cartilage defectsFocal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying…Focal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying problem.
